Clinical and treatment factors associated with the mortality of COVID-19 patients admitted to a referral hospital in Indonesia [0.03%]
与印度尼西亚转诊医院收治的COVID-19患者死亡率相关的临床和治疗因素
Yovita Hartantri,Josephine Debora,Leonardus Widyatmoko et al.
Yovita Hartantri et al.
Background: Indonesia had the second-highest number of COVID-19 cases and deaths in South-East Asia. We aimed to determine the factors associated with this mortality and the effect of the recommended COVID-19 treatment re...
Dietary weight-management for type 2 diabetes remissions in South Asians: the South Asian diabetes remission randomised trial for proof-of-concept and feasibility (STANDby) [0.03%]
南亚人群2型糖尿病缓解的饮食体重管理：概念验证和可行性试验（南亚糖尿病缓解随机对照试点研究）
Naveed Sattar,Paul Welsh,Wilma S Leslie et al.
Naveed Sattar et al.
Background: We aimed to assess whether a structured weight management programme incorporating a total diet replacement (TDR) (3-5 months ∼850 kcal/day formula diet) weight loss phase is acceptable to people of South Asia...
Effectiveness of Favipiravir monotherapy in the treatment of COVID-19: real world data analysis from Thailand [0.03%]
favipiravir单药治疗新冠肺炎疗效分析：泰国的真实世界数据研究
Attasit Srisubat,Somchai Thanasitthichai,Subsai Kongsaengdao et al.
Attasit Srisubat et al.
Background: Previous studies showed that Favipiravir, a selective viral ribonucleic acid dependent-ribonucleic acid polymerase inhibitor, exhibited a trend of clinical improvement within 14 days and promoted viral clearan...
The COVID-19 laboratory response in Timor-Leste; a story of collaboration [0.03%]
应对新冠肺炎疫情——东帝汶的团结抗疫故事
Nevio Sarmento,Endang Soares da Silva,Ismael Barreto et al.
Nevio Sarmento et al.
Timor-Leste is a small nation of 1.3 million people which shares a land border with Indonesia and is 550 km from Darwin, Australia. It is one of the poorest nations in Asia. The National Health Laboratory (NHL) and its network of smaller la...
Safety and efficacy of mycophenolate in COVID-19: a nonrandomised prospective study in western India [0.03%]
霉酚酸在COVID-19的安全性和有效性：印度西部的一项非随机前瞻性研究
Atul Sajgure,Ajit Kulkarni,Atul Joshi et al.
Atul Sajgure et al.
Background: Antivirals and immunosuppressive agents are used with variable success in the treatment of COVID-19. Mycophenolate, an inhibitor of enzyme inosine monophosphate dehydrogenase, is an immunosuppressant used to p...
Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study [0.03%]
牛津/阿斯利康新冠疫苗和印度版 Covaxin 加强针的同源与异源免疫原性及安全性：一项非劣效性研究
Winsley Rose,Reshma Raju,Sudhir Babji et al.
Winsley Rose et al.
Background: Primary SARS-CoV-2 vaccination has been shown to wane with time and provide lower protection from disease with new viral variants, prompting the WHO to recommend the administration of booster doses. We determi...
SARS-CoV-2 infection dynamics and genomic surveillance to detect variants in wastewater - a longitudinal study in Bengaluru, India [0.03%]
印度班加罗尔的纵向研究——通过废水中的感染动力学和基因组监测来检测变异病毒
Sanjay Lamba,Sutharsan Ganesan,Namrta Daroch et al.
Sanjay Lamba et al.
Background: Environmental surveillance (ES) of a pathogen is crucial for understanding the community load of disease. As an early warning system, ES for SARS-CoV-2 has complemented routine diagnostic surveillance by captu...
Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study [0.03%]
SII-NVX-CoV2373（新冠疫苗）在成人中的安全性及免疫原性：一项Ⅱ/Ⅲ期、观察者盲法、随机对照研究
Prasad S Kulkarni,Abhijit Kadam,Sheela Godbole et al.
Prasad S Kulkarni et al.
Background: NVX-CoV2373, a Covid-19 vaccine was developed in the USA with ∼90% efficacy. The same vaccine is manufactured in India after technology transfer (called as SII-NVX-CoV2373), was evaluated in this phase 2/3 im...
Common assumptions in tobacco control that may not hold true for South-East Asia [0.03%]
烟草控制中在东南亚可能不成立的普遍假设
Kamran Siddiqi,Monika Arora,Prakash C Gupta
Kamran Siddiqi
Tobacco is a threat to public health in South-East Asia and its control should be a priority. However, many common assumptions about tobacco control may not hold true for the region and can misdirect policy. The substantial health risks ass...